Novasenta
Mani Mohindru, PhD, is an accomplished executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as the Chief Executive Officer of Novasenta since April 2021, Mani also holds board positions at CytomX Therapeutics and Cardiff Oncology. In addition, Mani is an Executive Advisory Board Member at Northwestern University's Chemistry of Life Processes Institute. Previous leadership roles include CEO of CereXis, CFO and Chief Strategy Officer at Cara Therapeutics, and Chief Strategy Officer at Curis, Inc. Mani co-founded Immtox LLC and worked as a Senior Research Analyst at ThinkEquity LLC. Academic credentials include a PhD in Neurosciences from Northwestern University, a B.Sc (Hons) in Human Biology, and a Masters in Biotechnology from the All India Institute of Medical Sciences.
This person is not in any offices
Novasenta
1 followers
Novasenta develops treatments to transform the lives of patients with cancer. It uses systematic, rigorous, and unbiased human tumor microenvironment analysis to uncover new druggable targets, exploiting the critical interplay of disease, immune response, and metabolism. Single-cell level analysis of high-quality, human tumor samples combined withthe advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient. The company aims to identify novel targets to generate effective therapies for various cancers. It was founded in 2018 and is headquartered in Pittsburgh, Pennsylvania.